---
title: "Glenmark Pharmaceuticals Ltd (GLENMARK) — Share Price, Financials & Analysis"
symbol: "GLENMARK"
company: "Glenmark Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/GLENMARK"
isin: "INE935A01035"
nse_symbol: "GLENMARK"
bse_code: "532296"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 67572.98
generated_at: "2026-09-13T18:33:55.090Z"
---

# Glenmark Pharmaceuticals Ltd (GLENMARK)

Canonical page: https://tapetide.com/stocks/GLENMARK

## Company

- **NSE Symbol:** GLENMARK
- **BSE Code:** 532296
- **ISIN:** INE935A01035
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2000-02-07
- **CEO:** Mr. Glenn Mario Saldanha
- **Employees:** 15800
- **Face Value:** ₹1
- **F&O Eligible:** Yes
- **Website:** glenmarkpharma.com

## About

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]

## Latest Price

- **Price:** ₹2419.2
- **Change:** +4.2 (+0.17%)
- **Open:** ₹2411.2
- **Day High:** ₹2431.9
- **Day Low:** ₹2384.1
- **Previous Close:** ₹2415
- **Volume:** 346692
- **As Of:** 2026-09-11T10:28:33+00:00

## Key Fundamentals

Observed at 2026-09-11T04:46:59.865315Z.

- **Market Cap:** ₹67572.98 Cr
- **Classification:** Midcap
- **P/E (reported):** 37.9
- **P/E (TTM):** 37.97
- **EPS (TTM):** ₹63.71
- **EPS (reported):** ₹0
- **Book Value:** ₹372.47
- **Price to Book:** 6.49
- **Dividend Yield:** 0.21%
- **ROE:** 12.96%
- **ROCE:** 16.21%
- **Debt to Equity:** 0.06
- **Revenue (yearly):** ₹17443.1 Cr
- **Net Income:** ₹1362 Cr
- **EBITDA:** ₹5033 Cr
- **52-Week High:** ₹2537.6
- **52-Week Low:** ₹1792.6
- **RSI (14):** 54.35

## Tapetide Score

- **Score:** 53 / 100
- **Score date:** 2026-09-04
- **Archetype:** Cheap but Weak
- **What it means:** A low multiple sitting on weak financials. Worth establishing what the market is discounting before treating the low valuation as an opportunity — weak fundamentals often justify it.
- **Pillar profile:** Quality: Weak · Valuation: Cheap · Momentum: Falling
- **Percentile:** 61 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 54.91 | 9% |
| growth | 91.78 | 9% |
| momentum | 37.44 | 12% |
| ownership | 47.61 | 24% |
| quality | 39.8 | 22% |
| valuation | 64.02 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 19.4% CAGR over last 5 years

### Weaknesses

- The company has delivered a poor sales growth of 9.19% over past five years.
- Company has a low return on equity of -3.28% over last 3 years.
- Debtor days have increased from 85.2 to 107 days.
- Working capital days have increased from 41.2 days to 80.5 days

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 516.27% | — | 210.74% |
| ebitda margin growth | 37.99% | 57.22% | 79.3% | 44.68% |
| net income growth | 60.24% | 30.07% | 61% | 19% |
| revenue growth | 1.22% | 29.83% | 14% | 9% |
| roce | 62.04% | 1.76% | 150.54% | 11.35% |
| roe | 60.24% | 9.55% | 0.49% | 23.08% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 3207 | 2507 | 3063 | 3244 | 3434 | 3388 | 3256 | 3264 | 6047 | 3901 | 3771 | 4018 |
| Expenses | 2745 | 2715 | 2559 | 2656 | 2832 | 2787 | 2695 | 2684 | 3687 | 3031 | 3008 | 3214 |
| Operating Profit | 462 | -209 | 504 | 588 | 602 | 600 | 561 | 581 | 2360 | 870 | 763 | 805 |
| OPM % | 14 | -8 | 16 | 18 | 18 | 18 | 17 | 18 | 39 | 22 | 20 | 20 |
| Other Income | -205 | 87 | 351 | 31 | 39 | 31 | -361 | -297 | -1184 | -140 | -184 | 66 |
| Interest | 121 | 134 | 149 | 40 | 48 | 52 | 67 | 58 | 66 | 41 | 43 | 54 |
| Depreciation | 141 | 147 | 151 | 118 | 120 | 123 | 125 | 130 | 141 | 154 | 148 | 173 |
| Profit before tax | -6 | -403 | 555 | 462 | 473 | 456 | 8 | 96 | 967 | 534 | 388 | 643 |
| Tax % | 997 | -18 | 319 | 26 | 25 | 24 | 45 | 51 | 37 | 24 | 22 | 25 |
| Net Profit | -62 | -331 | -1214 | 340 | 354 | 348 | 4 | 47 | 610 | 403 | 301 | 483 |
| EPS in Rs | -2.9 | -12.45 | -43.17 | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 | 21.63 | 14.29 | 10.68 | 17.11 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 9074 | 9865 | 10641 | 10944 | 12305 | 11583 | 11813 | 13322 | 16983 | 17737 |
| Expenses | 7457 | 8280 | 8942 | 8860 | 9978 | 9948 | 10618 | 10970 | 12410 | 12940 |
| Operating Profit | 1617 | 1586 | 1699 | 2084 | 2327 | 1635 | 1195 | 2351 | 4572 | 4797 |
| OPM % | 18 | 16 | 16 | 19 | 19 | 14 | 10 | 18 | 27 | 27 |
| Other Income | 89 | 375 | 191 | 95 | -101 | -10 | 336 | -259 | -1805 | -1443 |
| Interest | 286 | 335 | 377 | 353 | 298 | 349 | 516 | 207 | 209 | 204 |
| Depreciation | 302 | 326 | 417 | 444 | 487 | 569 | 582 | 486 | 573 | 617 |
| Profit before tax | 1119 | 1301 | 1096 | 1382 | 1441 | 707 | 434 | 1399 | 1985 | 2533 |
| Tax % | 28 | 29 | 29 | 30 | 31 | 47 | 430 | 25 | 31 | — |
| Net Profit | 804 | 925 | 776 | 970 | 994 | 377 | -1434 | 1047 | 1362 | 1798 |
| EPS in Rs | 28.49 | 32.78 | 27.5 | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 | 48.26 | 63.71 |
| Dividend Payout % | 7 | 6 | 9 | 7 | 7 | 24 | -5 | 7 | 10 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| Reserves | 4464 | 5135 | 5577 | 6042 | 7036 | 9058 | 9446 | 7820 | 8821 | 10484 |
| Borrowings | 4724 | 4639 | 4449 | 4869 | 4986 | 3962 | 4608 | 1231 | 2473 | 594 |
| Other Liabilities | 2548 | 2793 | 3235 | 3729 | 3524 | 4003 | 5289 | 5279 | 4669 | 8801 |
| Total Liabilities | 11764 | 12595 | 13289 | 14668 | 15575 | 17052 | 19371 | 14358 | 15991 | 19907 |
| Fixed Assets | 2755 | 3030 | 3670 | 5029 | 5129 | 5887 | 5422 | 4210 | 4487 | 5915 |
| CWIP | 708 | 1122 | 1399 | 1222 | 1382 | 1010 | 1190 | 662 | 835 | 909 |
| Investments | 16 | 15 | 30 | 25 | 25 | 50 | 45 | 790 | 56 | 42 |
| Other Assets | 8285 | 8429 | 8190 | 8393 | 9040 | 10105 | 12715 | 8697 | 10613 | 13041 |
| Total Assets | 11764 | 12595 | 13289 | 14668 | 15575 | 17052 | 19371 | 14358 | 15991 | 19907 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 657 | 1648 | 1324 | 1392 | 1131 | 1109 | 625 | -265 | -828 | 3445 |
| Cash from Investing Activity | -1001 | -1003 | -883 | -774 | -662 | -316 | -515 | 4387 | 58 | -1237 |
| Cash from Financing Activity | 543 | -468 | -739 | -445 | -442 | -520 | -77 | -3906 | 787 | -2709 |
| Net Cash Flow | 199 | 177 | -297 | 174 | 28 | 272 | 32 | 215 | 17 | -501 |
| Free Cash Flow | -76 | 625 | 712 | 616 | 456 | 320 | 75 | -1162 | -1576 | 2090 |
| CFO/OP | 67 | 124 | 111 | 109 | 79 | 72 | 77 | 65 | -6 | 92 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 97 | 94 | 81 | 83 | 86 | 92 | 115 | 57 | 92 | 107 |
| Inventory Days | 299 | 244 | 244 | 211 | 230 | 208 | 203 | 208 | 254 | 264 |
| Days Payable | 243 | 225 | 241 | 210 | 226 | 190 | 172 | 210 | 256 | 288 |
| Cash Conversion Cycle | 152 | 113 | 85 | 84 | 90 | 110 | 147 | 56 | 90 | 83 |
| Working Capital Days | 125 | 99 | 64 | 54 | 67 | 65 | 141 | -2 | 44 | 81 |
| ROCE % | 21 | 15 | 15 | 14 | 15 | 16 | 10 | 12 | 19 | 40 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 46.65% | 46.65% | 46.64% | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% |
| FIIs | 24.8% | 23.71% | 21.38% | 20.98% | 23.05% | 23.51% | 23.16% | 20.62% | 20.73% | 19.2% | 20.34% | 20.89% |
| DIIs | 10.32% | 10.92% | 13.36% | 13.92% | 13.21% | 13.85% | 14.6% | 17.64% | 18.61% | 20.09% | 19.29% | 18.6% |
| Government | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| Public | 14.83% | 14.77% | 14.83% | 14.58% | 13.61% | 12.65% | 12.32% | 11.69% | 10.81% | 10.77% | 10.32% | 10.6% |
| Others | 3.37% | 3.92% | 3.75% | 3.83% | 3.45% | 3.31% | 3.24% | 3.37% | 3.16% | 3.26% | 3.36% | 3.21% |
| No. of Shareholders | 232685 | 209931 | 199451 | 192630 | 193949 | 195059 | 192724 | 190210 | 198789 | 201584 | 196105 | 211418 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 9 / 6 / 4

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 2450.22 | Sell |
| EMA (10) | 2434.41 | Sell |
| SMA (20) | 2411.87 | Buy |
| EMA (20) | 2408.27 | Buy |
| SMA (50) | 2316.74 | Buy |
| EMA (50) | 2341.14 | Buy |
| SMA (100) | 2291.01 | Buy |
| EMA (100) | 2279.8 | Buy |
| SMA (200) | 2169.94 | Buy |
| EMA (200) | 2168.16 | Buy |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 54.91 | Neutral |
| MACD (12,26,9) | 39.8 | Sell |
| Stochastic (14,3,3) | 44.6 | Neutral |
| ADX (14) | 23.72 | Neutral |
| Williams %R (14) | -73.27 | Neutral |
| ATR (14) | 57.39 | Neutral |
| ROC (12) | -0.78 | Sell |
| Stoch RSI (14) | 2.93 | Buy |
| UO (7,14,28) | 55.2 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 6 | 75% |
| Hold | 2 | 25% |
| Sell | 0 | 0% |

Based on 8 analyst ratings, observed at 2026-09-11T04:46:59.834733+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-11 | [Announcement under Regulation 30 (LODR)-Credit Rating](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5831f24e-22ea-4ddf-a378-cff9127b1ea1.pdf) |
| 2026-09-11 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=85017909-f0cf-494a-ac05-40c865abb10f.pdf) |
| 2026-08-21 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=538561c0-9f8c-4222-9166-6eca04d49f70.pdf) |
| 2026-08-20 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6f33378b-b3c4-4216-8be1-16bcad15693d.pdf) |
| 2026-08-15 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98da0bf3-657b-4248-abcd-a617ae84de93.pdf) |
| 2026-08-13 | [Notice Of The 48Th Annual General Meeting For The Financial Year 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=020c8973-14f7-4600-8af2-07479055a382.pdf) |
| 2026-08-13 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1372ff9a-9fa7-4106-979e-d0cfe5c5f8e8.pdf) |
| 2026-08-13 | [Business Responsibility and Sustainability Reporting (BRSR)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a0275cfd-5681-42a5-935d-b2020efa013b.pdf) |
| 2026-08-13 | [Letter To Shareholders Whose Email Address Are Not Registered Providing The Web Link Of Annual Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=70dbdcca-1a8d-47e9-b34d-9fdecf39c097.pdf) |
| 2026-08-11 | [Settlement Agreement - Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=95e614de-03e1-4ee7-9321-a52a7a9c6c17.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Apr - Glenmark receives U.S. FDA approval for Progesterone Vaginal Inserts, 100 mg; U.S. market sales ~$59.2 million. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 9 Apr - Glenmark receives U.S. FDA approval for Progesterone Vaginal Inserts, 100 mg; U.S. market sales ~$59.2 million.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a92560cf-a496-470e-acb2-c05b14b81487.pdf) |
| 4 Mar - FDA approves Fluticasone Propionate inhalation 44 mcg; 180-day CGT exclusivity; U.S. launch March 2026; $520.1M RLD market. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 4 Mar - FDA approves Fluticasone Propionate inhalation 44 mcg; 180-day CGT exclusivity; U.S. launch March 2026; $520.1M RLD market.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c9278371-7b88-47ab-9859-469778b997a2.pdf) |
| 4 Feb - Transcript of the Earnings Call held on Monday, February 02, 2026 has been uploaded on the Company''s website. | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript 4 Feb - Transcript of the Earnings Call held on Monday, February 02, 2026 has been uploaded on the Company''s website.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e557fd6c-8af4-4ae2-9928-68d5f083c904.pdf) |
| 30 Apr - Glenmark confirms it is not a Large Corporate under SEBI disclosure criteria. | [Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 30 Apr - Glenmark confirms it is not a Large Corporate under SEBI disclosure criteria.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/898fe2b8-a916-459c-a981-de2b9d53b331.pdf) |
| 30 Apr - Glenmark confirms it is not a Large Corporate under SEBI disclosure criteria. | [Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 30 Apr - Glenmark confirms it is not a Large Corporate under SEBI disclosure criteria.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/898fe2b8-a916-459c-a981-de2b9d53b331.pdf) |
| 30 Apr - Glenmark confirms it is not a Large Corporate under SEBI circular requirements. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - Glenmark confirms it is not a Large Corporate under SEBI circular requirements.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8d53b48a-0e7a-4c7b-ada1-4dd70338c3cc.pdf) |
| 30 Apr - Glenmark confirms it is not a Large Corporate under SEBI circular requirements. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - Glenmark confirms it is not a Large Corporate under SEBI circular requirements.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/8d53b48a-0e7a-4c7b-ada1-4dd70338c3cc.pdf) |
| 27 Feb - Glenmark to distribute Sodium Phosphates Injection in US from April 2026; market ~ $66.8M annual sales. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 27 Feb - Glenmark to distribute Sodium Phosphates Injection in US from April 2026; market ~ $66.8M annual sales.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bd5c07d6-9e23-4311-a194-d7bab64b84c0.pdf) |
| 21 Mar - Launched GLIPIQ (semaglutide) in India March 21, 2026; weekly cost ₹325–₹440; vial and pre-filled pens available. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 21 Mar - Launched GLIPIQ (semaglutide) in India March 21, 2026; weekly cost ₹325–₹440; vial and pre-filled pens available.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4f528c87-3253-4f20-892a-90ab1d094260.pdf) |
| 20 Feb - NSE Sustainability assigned Glenmark an ESG rating of 68 for FY2025 (email dated Feb 20, 2026). | [Announcement Under Regulation 30 Of The SEBI LODR 20 Feb - NSE Sustainability assigned Glenmark an ESG rating of 68 for FY2025 (email dated Feb 20, 2026).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2b59bcf5-c4ac-4d4f-b41d-d1f029ffe118.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-05 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7635e0f9-5e06-4194-9dff-4c5437880c6d.pdf) |
| 2026-06-05 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c698c9c2-2d25-4855-8dd2-39cb378220f8.pdf) |
| 2026-02-04 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e557fd6c-8af4-4ae2-9928-68d5f083c904.pdf) |
| 2025-11-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c995d72a-dd22-44a4-a163-01fcfee9a18e.pdf) |
| 2025-05-27 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b8d7f8ed-6f40-476a-914a-2b00435fa31a.pdf) |
| 2025-02-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7b9efbda-ee4a-4042-91ea-1698580069eb.pdf) |
| 2024-11-21 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7a5cc6e3-bbc1-473a-9506-b5999588c822.pdf) |
| 2024-08-20 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e07f0ee2-79b8-419c-be62-6a5911f989ca.pdf) |
| 2024-05-29 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12c38fea-32b1-4125-a8d1-a580478385fe.pdf) |
| 2024-02-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8af58f75-5319-4b22-ba23-4d25e7365312.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-03 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=16e00e98-09fb-4334-8886-2b5a8df709e8.pdf) |
| 2026-06-01 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b57d0d16-3dea-47fd-875f-d661871fec92.pdf) |
| 2026-02-02 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dbc49df8-9d42-4521-b7be-1f74e8a53b1c.pdf) |
| 2025-11-17 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f588bf04-ebbe-402b-abcd-1b8e6aa897b4.pdf) |
| 2025-07-23 | [Audio Recording Of The Glenmark Pharmaceuticals Limited - Investor Day 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=740ed0cc-a602-497e-975f-1c66c12d2b1b.pdf) |
| 2025-05-26 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ebf8a7bf-f74a-428a-a36d-85b0be147fff.pdf) |
| 2024-11-18 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a696c3d7-be75-40a1-a8d5-a8131b4753e4.pdf) |
| 2024-08-16 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac617c07-2608-473b-8fac-6da9dfd020f3.pdf) |
| 2024-05-31 | [Audio Recording Of The Glenmark Pharmaceuticals Limited - Investor Day 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=263b21b1-5361-4d4a-b408-436169f88361.pdf) |
| 2024-05-27 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f283cf7-82fe-4d69-885e-87210a76a5b2.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2023 | [Concall - Sep 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c8382289-c246-4331-9ebf-53a00bbf84e6.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c213bac9-eced-4c2f-99e2-de5c3260f970.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/72f9262f-5b86-4fab-8639-43767096f2fa.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/2009b465-cba9-4a83-9890-e9c79c9b7070.pdf) |
| May 2021 | [Concall - May 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d2b03464-b23e-4e55-94a7-dc0a02aaabdf.pdf) |
| Jun 2026 | [Concall - Jun 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2009b465-cba9-4a83-9890-e9c79c9b7070.pdf) |
| Jul 2025 | [Concall - Jul 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5659eafc-f281-4f83-bbde-3c181a311e99.pdf) |
| Feb 2022 | [Concall - Feb 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/97854b39-1e67-449e-9644-c90583014762.pdf) |
| Aug 2021 | [Concall - Aug 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/27fbba66-db64-4f74-b0f8-28eb4b453333.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-07-31 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e9f422b3-3967-4f79-a9e6-1579607afa25.pdf) |
| 2026-06-09 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1cd1d4c3-e7c3-4181-8a4a-f9368c3ab2fe.pdf) |
| 2026-05-29 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2009b465-cba9-4a83-9890-e9c79c9b7070.pdf) |
| 2026-01-30 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=856749e4-3647-45da-8001-1814468ab0bc.pdf) |
| 2025-11-14 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=56fa1426-7a72-499d-8b43-3b4d1fad129f.pdf) |
| 2025-08-14 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d6139070-f93f-4e0b-b520-cdcf5431009a.pdf) |
| 2025-07-16 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5659eafc-f281-4f83-bbde-3c181a311e99.pdf) |
| 2025-05-23 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4caf64a2-3797-4495-8cea-68f00d80fc01.pdf) |
| 2025-02-14 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6dc274d1-2f3b-4867-afd7-26f68eed8911.pdf) |
| 2024-11-14 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=85d2b081-3caf-4aef-b2dc-8d3e51336c19.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1372ff9a-9fa7-4106-979e-d0cfe5c5f8e8.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d3b75907-c1d1-4607-a8d1-7b01cf5078af.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fafa0cb9-ee50-4ae1-abcd-a4d4fe91cd14.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/038d73a5-f6a4-4810-a1d3-94e5d02888c8.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/532296/74780532296.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2025-08-14 | [Unaudited Financial Results (Standalone And Consolidated) For The First Quarter Ended 30Th June 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b72a6b85-71e4-4be2-a5d3-39c2effe26cd.pdf) |
| 2024-02-14 | [Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended December 31, 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9664d8f2-05c6-4fb7-983f-1683b177590b.pdf) |
| 2023-11-10 | [Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended 30Th September, 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cd21a91c-2316-4e78-9509-cf52e9c498de.pdf) |
| 2023-08-11 | [Unaudited Financial Results (Standalone And Consolidated) For The First Quarter Ended 30Th June, 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=33e95a36-ca7c-4bcd-b529-08fc784b39ac.pdf) |
| 2023-05-19 | [Audited Financial Results For The Quarter And Year Ended March 31, 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c395378e-d7d1-4206-9d4d-1318793dd88b.pdf) |
| 2023-02-10 | [Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended December 31, 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=66e798c3-956e-4c7f-9b1a-86d560dcc215.pdf) |
| 2022-11-25 | [Disclosure Of Related Party Transactions For The Half Year Ended 30Th September, 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bd0ea7d2-6298-4c5e-833c-aba49c3c9e39.pdf) |
| 2022-11-11 | [Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended September 30, 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c213bac9-eced-4c2f-99e2-de5c3260f970.pdf) |
| 2022-08-10 | [Unaudited Financial Results Standalone And Consolidated For The First Quarter Ended June 30, 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0af2818f-d831-426b-9449-1abf28c25eb7.pdf) |
| 2022-06-10 | [Disclosure Of Related Party Transactions For The Half Year Ended 31St March, 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0de130e4-b62b-4e83-bf55-77ef01d0da27.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:33:55.090Z.